AI Solutions Take Centre Stage At The Annual Transfusion Medicine Update Conference In Abu Dhabi

The 2025 Annual Transfusion Medicine Update Conference commenced on 14 November 2025 in Abu Dhabi. This event gathers leading experts in transfusion medicine, laboratory sciences, and clinical practice from across the globe. Attendees include specialists from the USA, Canada, Japan, and GCC countries, along with representatives from over ten international companies in pharmaceuticals and medical devices.

Dr. Eiman Al Zaabi, Chair of Pathology and Laboratory Medicine at Sheikh Shakhbout Medical City and Chair of the Conference, highlighted the event's significance as a premier medical conference in the region. She stated that it serves as a scientific hub for global experts to collaborate on advancing transfusion medicine and improving clinical practices.

Dr. Al Zaabi emphasised the conference's focus on gene therapy's future impact on patient outcomes. The integration of artificial intelligence (AI) into transfusion medicine is also a key topic. AI is now crucial in laboratory operations, aiding in patient stratification and suitability assessments for gene therapy by linking lab results to clinical cases.

She further explained that AI is revolutionising large patient dataset analysis, reducing time and effort for specialists while enhancing access to global research. This enriches medical knowledge and improves diagnostic accuracy and therapeutic outcomes.

Pharmaceutical companies are vital partners in this conference due to their support in integrating AI into blood bank devices. These technologies enhance data analysis speed and operational efficiency, allowing technologists to achieve accurate results more quickly.

The scientific committee has developed a comprehensive program with international experts. It includes research presentations evaluated by rigorous academic standards, focusing on innovations in transfusion medicine.

Strengthening Global Partnerships

Dr. Hiba Saud Alhumaidan from "Dubai Health" noted that the conference offers a unique platform for exchanging expertise among global specialists in transfusion medicine and cellular therapies. It aims to strengthen scientific partnerships between clinical and research centres worldwide.

The event promotes local and international cooperation to benefit both the medical community and researchers by advancing practices in transfusion medicine and cellular therapies.

Advancements in Bone Marrow Transplantation

The conference addresses new technologies for managing complications after bone marrow transplantation, such as Graft vs Host Disease (GVHD). The goal is to reduce complications and improve patient outcomes post-transplantation.

Dr. Hiba highlighted advancements in gene therapy within laboratory models and the promising future of in vivo gene therapy. She affirmed that AI-driven solutions are enhancing laboratory performance, elevating transfusion medicine practices for faster healthcare services.

This conference underscores its role as a key platform for showcasing global advancements under one roof while fostering collaboration among medical institutions worldwide.

With inputs from WAM